JP7293220B2 - アレルギーの処置のための組成物および方法 - Google Patents

アレルギーの処置のための組成物および方法 Download PDF

Info

Publication number
JP7293220B2
JP7293220B2 JP2020526142A JP2020526142A JP7293220B2 JP 7293220 B2 JP7293220 B2 JP 7293220B2 JP 2020526142 A JP2020526142 A JP 2020526142A JP 2020526142 A JP2020526142 A JP 2020526142A JP 7293220 B2 JP7293220 B2 JP 7293220B2
Authority
JP
Japan
Prior art keywords
sequence
seq
nucleic acid
bacterial strain
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020526142A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021502391A (ja
JP2021502391A5 (enExample
Inventor
ザバディ，ローズ，エル．
オレ，ベルナー
ロバーツ，ブルース
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vedanta Biosciences Inc
Original Assignee
Vedanta Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vedanta Biosciences Inc filed Critical Vedanta Biosciences Inc
Publication of JP2021502391A publication Critical patent/JP2021502391A/ja
Publication of JP2021502391A5 publication Critical patent/JP2021502391A5/ja
Priority to JP2023093879A priority Critical patent/JP2023121755A/ja
Application granted granted Critical
Publication of JP7293220B2 publication Critical patent/JP7293220B2/ja
Priority to JP2025105253A priority patent/JP2025170783A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020526142A 2017-11-09 2018-11-09 アレルギーの処置のための組成物および方法 Active JP7293220B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023093879A JP2023121755A (ja) 2017-11-09 2023-06-07 アレルギーの処置のための組成物および方法
JP2025105253A JP2025170783A (ja) 2017-11-09 2025-06-23 アレルギーの処置のための組成物および方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762583777P 2017-11-09 2017-11-09
US62/583,777 2017-11-09
US201862637355P 2018-03-01 2018-03-01
US62/637,355 2018-03-01
US201862721786P 2018-08-23 2018-08-23
US62/721,786 2018-08-23
PCT/US2018/060187 WO2019094837A1 (en) 2017-11-09 2018-11-09 Compositions and methods for the treatment of allergy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023093879A Division JP2023121755A (ja) 2017-11-09 2023-06-07 アレルギーの処置のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2021502391A JP2021502391A (ja) 2021-01-28
JP2021502391A5 JP2021502391A5 (enExample) 2021-12-16
JP7293220B2 true JP7293220B2 (ja) 2023-06-19

Family

ID=66438676

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020526142A Active JP7293220B2 (ja) 2017-11-09 2018-11-09 アレルギーの処置のための組成物および方法
JP2023093879A Pending JP2023121755A (ja) 2017-11-09 2023-06-07 アレルギーの処置のための組成物および方法
JP2025105253A Pending JP2025170783A (ja) 2017-11-09 2025-06-23 アレルギーの処置のための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023093879A Pending JP2023121755A (ja) 2017-11-09 2023-06-07 アレルギーの処置のための組成物および方法
JP2025105253A Pending JP2025170783A (ja) 2017-11-09 2025-06-23 アレルギーの処置のための組成物および方法

Country Status (7)

Country Link
US (1) US20220054556A1 (enExample)
EP (1) EP3706767A4 (enExample)
JP (3) JP7293220B2 (enExample)
CN (1) CN111526882A (enExample)
AU (1) AU2018365071B2 (enExample)
CA (1) CA3081978A1 (enExample)
WO (1) WO2019094837A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4410954A3 (en) 2017-12-11 2025-01-15 Vedanta Biosciences, Inc. Compositions and methods for suppressing pathogenic organisms
JP2022549133A (ja) * 2019-09-16 2022-11-24 ヴェダンタ バイオサイエンシーズ インコーポレーテッド 細菌を保存するための方法および組成物
EP4294413A1 (en) 2021-02-18 2023-12-27 Vedanta Biosciences, Inc. Compositions and methods for suppressing pathogenic organisms

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015500792A (ja) 2011-12-01 2015-01-08 国立大学法人 東京大学 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌
WO2015095241A2 (en) 2013-12-16 2015-06-25 Seres Health, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
WO2017079450A1 (en) 2015-11-03 2017-05-11 The Brigham And Women's Hospital Therapeutic microbiota for the treatment and/or prevention of food allergy
JP7168558B2 (ja) 2016-06-14 2022-11-09 ヴェダンタ バイオサイエンシーズ インコーポレーテッド Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101253199B (zh) * 2005-08-30 2019-06-14 迈阿密大学 免疫调节肿瘤坏死因子受体25(tnfr25)的激动剂、拮抗剂和免疫毒素
US8906668B2 (en) * 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
JP6617935B2 (ja) * 2014-04-10 2019-12-11 国立研究開発法人理化学研究所 Ｔｈ１７細胞の誘導のための組成物及び方法
US11260083B2 (en) * 2016-03-15 2022-03-01 The Regents Of The University Of Michigan Compositions and methods for treating and preventing graft versus host disease
US9999641B2 (en) * 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
WO2018187272A1 (en) * 2017-04-03 2018-10-11 Gusto Global, Llc Rational design of microbial-based biotherapeutics
US10507221B2 (en) * 2017-11-09 2019-12-17 Vedanta Biosciences, Inc. Compositions and methods for the treatment of allergy
CN114502183A (zh) * 2019-08-09 2022-05-13 韦丹塔生物科学股份有限公司 用于阻抑病原生物体的组合物和方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015500792A (ja) 2011-12-01 2015-01-08 国立大学法人 東京大学 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌
WO2015095241A2 (en) 2013-12-16 2015-06-25 Seres Health, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
WO2017079450A1 (en) 2015-11-03 2017-05-11 The Brigham And Women's Hospital Therapeutic microbiota for the treatment and/or prevention of food allergy
JP7168558B2 (ja) 2016-06-14 2022-11-09 ヴェダンタ バイオサイエンシーズ インコーポレーテッド Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置

Also Published As

Publication number Publication date
JP2023121755A (ja) 2023-08-31
EP3706767A4 (en) 2021-12-15
WO2019094837A1 (en) 2019-05-16
JP2021502391A (ja) 2021-01-28
EP3706767A1 (en) 2020-09-16
JP2025170783A (ja) 2025-11-19
AU2018365071B2 (en) 2025-09-11
US20220054556A1 (en) 2022-02-24
AU2018365071A1 (en) 2020-05-21
CA3081978A1 (en) 2019-05-16
CN111526882A (zh) 2020-08-11

Similar Documents

Publication Publication Date Title
US11000556B2 (en) Compositions and methods for the treatment of allergy
JP2023121755A (ja) アレルギーの処置のための組成物および方法
JP6492151B2 (ja) 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌
TWI821168B (zh) 誘導cd8+ t細胞的組成物及方法
CN103079582B (zh) 诱导调节性t细胞的增殖或积累的组合物
US10071157B2 (en) Method of inducing tolerance to an allergen
KR20230074531A (ko) 자가면역 질환을 치료 및/또는 예방하기 위한 조성물 및 방법
HK40036038A (en) Compositions and methods for the treatment of allergy
HK1261280B (en) Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
Miles Adverse immune reactions to foods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211108

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230510

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230607

R150 Certificate of patent or registration of utility model

Ref document number: 7293220

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150